124 related articles for article (PubMed ID: 17679479)
21. Pharmacokinetics and safety of intrathecal liposomal cytarabine in children aged <3 years.
Peyrl A; Sauermann R; Traunmueller F; Azizi AA; Gruber-Olipitz M; Gupper A; Slavc I
Clin Pharmacokinet; 2009; 48(4):265-71. PubMed ID: 19492871
[TBL] [Abstract][Full Text] [Related]
22. Intracranial hypertension following intrathecal administration of liposomal cytarabine.
Lunskens S; Lammertijn L; Deeren D; Bergmans B; Maertens J; Vandenberghe R
J Neurol; 2011 Jan; 258(1):162-3. PubMed ID: 20706845
[No Abstract] [Full Text] [Related]
23. Neurotoxicity of intra-CSF liposomal cytarabine (DepoCyt) administered for the treatment of leptomeningeal metastases: a retrospective case series.
Chamberlain MC
J Neurooncol; 2012 Aug; 109(1):143-8. PubMed ID: 22539243
[TBL] [Abstract][Full Text] [Related]
24. New liposomal cytarabine formulation in CSF.
Casado P; Torreira C; Oujo E; Esteban P; Albo C; Diaz R; Andrade MA
Clin Lab; 2010; 56(1-2):69-70. PubMed ID: 20380362
[No Abstract] [Full Text] [Related]
25. Intrathecal depot cytarabine therapy: a welcome addition to a limited armamentarium.
Bleyer WA
Clin Cancer Res; 1999 Nov; 5(11):3349-51. PubMed ID: 10589743
[No Abstract] [Full Text] [Related]
26. Liposomal cytarabine in neoplastic meningitis from primary brain tumors: a single institutional experience.
Gaviani P; Corsini E; Salmaggi A; Lamperti E; Botturi A; Erbetta A; Milanesi I; Legnani F; Pollo B; Silvani A
Neurol Sci; 2013 Dec; 34(12):2151-7. PubMed ID: 23525755
[TBL] [Abstract][Full Text] [Related]
27. Results of compassionate therapy with intrathecal depot liposomal cytarabine in acute myeloid leukemia meningeosis.
Sancho JM; Deben G; Parker A; Piñana JL; Bolam S; Sánchez-García E; Giménez E; Pascual T; Fernández-Abellán P; Palomera L; Ribera JM
Int J Hematol; 2007 Jul; 86(1):33-6. PubMed ID: 17675264
[TBL] [Abstract][Full Text] [Related]
28. Safety and toxicity of intrathecal liposomal cytarabine (Depocyte) in children and adolescents with recurrent or refractory brain tumors: a multi-institutional retrospective study.
Benesch M; Siegler N; Hoff Kv; Lassay L; Kropshofer G; Müller H; Sommer C; Rutkowski S; Fleischhack G; Urban C
Anticancer Drugs; 2009 Oct; 20(9):794-9. PubMed ID: 19617818
[TBL] [Abstract][Full Text] [Related]
29. Analysis of the role of intratecal liposomal cytarabine in the prophylaxis and treatment of central nervous system lymphomatosis: The Balearic Lymphoma Group experience.
García-Recio M; Cladera A; Bento L; Dominguez J; Ruiz de Gracia S; Sartori F; Del Campo R; García L; Ballester C; Gines J; Bargay J; Sampol A; Gutiérrez A
PLoS One; 2017; 12(6):e0179595. PubMed ID: 28665999
[TBL] [Abstract][Full Text] [Related]
30. Spurious pleocytosis.
Mathai S; Jones GL
Blood; 2010 Aug; 116(5):678. PubMed ID: 20722103
[No Abstract] [Full Text] [Related]
31. Neuroophthalmological side effects following intrathecal administration of liposomal cytarabine for central nervous system prophylaxis in three adolescents with acute myeloid leukaemia.
Sommer C; Lackner H; Benesch M; Sovinz P; Schwinger W; Moser A; Bergloeff J; Gruber A; Urban C
Ann Hematol; 2008 Nov; 87(11):887-90. PubMed ID: 18575860
[TBL] [Abstract][Full Text] [Related]
32. Cerebrospinal Fluid Drug Concentrations and Clinical Outcome of Patients with Neoplastic Meningitis Treated with Liposomal Cytarabine.
Bohn JP; Reinstadler V; Pall G; Stockhammer G; Steurer M; Oberacher H; Wolf D
Eur J Drug Metab Pharmacokinet; 2019 Dec; 44(6):845-851. PubMed ID: 31435852
[TBL] [Abstract][Full Text] [Related]
33. Neurological and cytological response as potential early predictors of time-to-progression and overall survival in patients with leptomeningeal carcinomatosis treated with intrathecal liposomal cytarabine: a retrospective cohort study.
Fusco JP; Castañón E; Carranza OE; Zubiri L; Martín P; Espinós J; Rodríguez J; Santisteban M; Aramendía JM; Gil-Bazo I
J Neurooncol; 2013 Dec; 115(3):429-35. PubMed ID: 24037499
[TBL] [Abstract][Full Text] [Related]
34. A pharmacokinetic study of intra-CSF administered encapsulated cytarabine (DepoCyt) for the treatment of neoplastic meningitis in patients with leukemia, lymphoma, or solid tumors as part of a phase III study.
Phuphanich S; Maria B; Braeckman R; Chamberlain M
J Neurooncol; 2007 Jan; 81(2):201-8. PubMed ID: 16941075
[TBL] [Abstract][Full Text] [Related]
35. Current treatment approaches for neoplastic meningitis: nursing management of patients receiving intrathecal DepoCyt.
Craig C
Oncol Nurs Forum; 2000 Sep; 27(8):1225-30; quiz 1231-2. PubMed ID: 11013903
[TBL] [Abstract][Full Text] [Related]
36. Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis.
Glantz MJ; LaFollette S; Jaeckle KA; Shapiro W; Swinnen L; Rozental JR; Phuphanich S; Rogers LR; Gutheil JC; Batchelor T; Lyter D; Chamberlain M; Maria BL; Schiffer C; Bashir R; Thomas D; Cowens W; Howell SB
J Clin Oncol; 1999 Oct; 17(10):3110-6. PubMed ID: 10506606
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics and toxicity of intrathecal liposomal cytarabine in children and adolescents following age-adapted dosing.
Peyrl A; Sauermann R; Chocholous M; Azizi AA; Jäger W; Höferl M; Slavc I
Clin Pharmacokinet; 2014 Feb; 53(2):165-73. PubMed ID: 24129691
[TBL] [Abstract][Full Text] [Related]
38. Comparison of leukopenia between cytarabine and behenoyl cytarabine in JALSG AML-89 consolidation therapy. The Japan Adult Leukemia Study Group.
Miyawaki S; Kobayashi T; Tanimoto M; Kuriyama K; Murakami H; Yoshida M; Minami S; Minato K; Tsubaki K; Omoto E; Oh H; Jinnai I; Sakamaki H; Hiraoka A; Kanamaru A; Takahashi I; Saito K; Naoe T; Yamada O; Asou N; Kageyama S; Emi N; Ueda T; Tomonaga M; Ohno R
Int J Hematol; 1999 Jul; 70(1):56-7. PubMed ID: 10446497
[No Abstract] [Full Text] [Related]
39. Efficacy and safety of liposomal cytarabine in lymphoma patients with central nervous system involvement from lymphoma.
Garcia-Marco JA; Panizo C; Garcia ES; Deben G; Alvarez-Larran A; Barca EG; Sancho JM; Penarrubia MJ; Garcia-Cerecedo T; Garcia Vela JA
Cancer; 2009 May; 115(9):1892-8. PubMed ID: 19235254
[TBL] [Abstract][Full Text] [Related]
40. Central nervous system prophylaxis with intrathecal liposomal cytarabine in a subset of high-risk patients with diffuse large B-cell lymphoma receiving first line systemic therapy in a prospective trial.
González-Barca E; Canales M; Salar A; Ferreiro-Martínez JJ; Ferrer-Bordes S; García-Marco JA; Sánchez-Blanco JJ; García-Frade J; Peñalver J; Bello-López JL; Sancho JM; Caballero D;
Ann Hematol; 2016 May; 95(6):893-9. PubMed ID: 27025508
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
